These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31385978)

  • 41. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
    Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
    Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of the EORTC QLQ-C30 questionnaire: a comparison with SF-36 Health Survey in a cohort of Italian long-survival cancer patients.
    Apolone G; Filiberti A; Cifani S; Ruggiata R; Mosconi P
    Ann Oncol; 1998 May; 9(5):549-57. PubMed ID: 9653497
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Symptoms and quality of life in chronic pancreatitis assessed by structured interview and the EORTC QLQ-C30 and QLQ-PAN26.
    Fitzsimmons D; Kahl S; Butturini G; van Wyk M; Bornman P; Bassi C; Malfertheiner P; George SL; Johnson CD
    Am J Gastroenterol; 2005 Apr; 100(4):918-26. PubMed ID: 15784041
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Updated EORTC QLQ-C30 general population norm data for Germany.
    Nolte S; Waldmann A; Liegl G; Petersen MA; Groenvold M; Rose M;
    Eur J Cancer; 2020 Sep; 137():161-170. PubMed ID: 32777715
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients.
    Dirven L; Musoro JZ; Coens C; Reijneveld JC; Taphoorn MJB; Boele FW; Groenvold M; van den Bent MJ; Stupp R; Velikova G; Cocks K; Sprangers MAG; King MT; Flechtner HH; Bottomley A
    Neuro Oncol; 2021 Aug; 23(8):1327-1336. PubMed ID: 33598685
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research.
    Giesinger JM; Loth FLC; Aaronson NK; Arraras JI; Caocci G; Efficace F; Groenvold M; van Leeuwen M; Petersen MA; Ramage J; Tomaszewski KA; Young T; Holzner B;
    J Clin Epidemiol; 2020 Feb; 118():1-8. PubMed ID: 31639445
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Thresholds for clinical importance for four key domains of the EORTC QLQ-C30: physical functioning, emotional functioning, fatigue and pain.
    Giesinger JM; Kuijpers W; Young T; Tomaszewski KA; Friend E; Zabernigg A; Holzner B; Aaronson NK
    Health Qual Life Outcomes; 2016 Jun; 14():87. PubMed ID: 27267486
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Occurrence and predictors of the fatigue in high-grade glioma patients.
    Aprile I; Chiesa S; Padua L; Di Blasi C; Arezzo MF; Valentini V; Di Stasio E; Balducci M
    Neurol Sci; 2015 Aug; 36(8):1363-9. PubMed ID: 25698127
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of neuropsychological outcome and "quality of life" after glioma surgery.
    Wolf J; Campos B; Bruckner T; Vogt L; Unterberg A; Ahmadi R
    Langenbecks Arch Surg; 2016 Jun; 401(4):541-9. PubMed ID: 27030244
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Health-related quality of life in patients with lung cancer: validation of the Mexican-Spanish version and association with prognosis of the EORTC QLQ-LC13 questionnaire.
    Arrieta Ó; Núñez-Valencia C; Reynoso-Erazo L; Alvarado S; Flores-Estrada D; Angulo LP; Oñate-Ocaña LF
    Lung Cancer; 2012 Jul; 77(1):205-11. PubMed ID: 22387006
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Screening for distress in patients with intracranial tumors during the first 6 months after diagnosis using self-reporting instruments and an expert rating scale (the basic documentation for psycho-oncology short form - PO-Bado SF).
    Renovanz M; Tsakmaklis H; Soebianto S; Neppel I; Nadji-Ohl M; Beutel M; Werner A; Ringel F; Hickmann AK
    Oncotarget; 2018 Jul; 9(57):31133-31145. PubMed ID: 30123432
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Validity and reliability of the Swedish version of the Memorial Symptom Assessment Scale (MSAS): an instrument for the evaluation of symptom prevalence, characteristics, and distress.
    Browall M; Kenne Sarenmalm E; Nasic S; Wengström Y; Gaston-Johansson F
    J Pain Symptom Manage; 2013 Jul; 46(1):131-41. PubMed ID: 23195392
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identifying cutoff scores for the EORTC QLQ-C30 and the head and neck cancer-specific module EORTC QLQ-H&N35 representing unmet supportive care needs in patients with head and neck cancer.
    Jansen F; Snyder CF; Leemans CR; Verdonck-de Leeuw IM
    Head Neck; 2016 Apr; 38 Suppl 1():E1493-500. PubMed ID: 27111696
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Multinational Pilot Study on Patients' Perceptions of Advanced Neuroendocrine Neoplasms on the EORTC QLQ-C30 and EORTC QLQ-GINET21 Questionnaires.
    van Leeuwaarde RS; González-Clavijo AM; Pracht M; Emelianova G; Cheung WY; Thirlwell C; Öberg K; Spada F
    J Clin Med; 2022 Feb; 11(5):. PubMed ID: 35268362
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study.
    Van Cutsem E; Valderrama A; Bang YJ; Fuchs CS; Shitara K; Janjigian YY; Qin S; Larson TG; Shankaran V; Stein S; Norquist JM; Kher U; Shah S; Alsina M
    ESMO Open; 2021 Aug; 6(4):100189. PubMed ID: 34371381
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients.
    Maringwa J; Quinten C; King M; Ringash J; Osoba D; Coens C; Martinelli F; Reeve BB; Gotay C; Greimel E; Flechtner H; Cleeland CS; Schmucker-Von Koch J; Weis J; Van Den Bent MJ; Stupp R; Taphoorn MJ; Bottomley A;
    Ann Oncol; 2011 Sep; 22(9):2107-2112. PubMed ID: 21324954
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group.
    Bjordal K; de Graeff A; Fayers PM; Hammerlid E; van Pottelsberghe C; Curran D; Ahlner-Elmqvist M; Maher EJ; Meyza JW; Brédart A; Söderholm AL; Arraras JJ; Feine JS; Abendstein H; Morton RP; Pignon T; Huguenin P; Bottomly A; Kaasa S
    Eur J Cancer; 2000 Sep; 36(14):1796-807. PubMed ID: 10974628
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mapping the EORTC QLQ-C30 and QLQ-H&N35 to the EQ-5D for head and neck cancer: Can disease-specific utilities be obtained?
    Beck ACC; Kieffer JM; Retèl VP; van Overveld LFJ; Takes RP; van den Brekel MWM; van Harten WH; Stuiver MM
    PLoS One; 2019; 14(12):e0226077. PubMed ID: 31834892
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The validation of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) in pre-operative patients with brain tumor in China.
    Cheng JX; Liu BL; Zhang X; Zhang YQ; Lin W; Wang R; Zhang YQ; Zhang HY; Xie L; Huo JL
    BMC Med Res Methodol; 2011 Apr; 11():56. PubMed ID: 21513533
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The EORTC Quality of Life Questionnaire for cancer patients (QLQ-C30): Australian general population reference values.
    Mercieca-Bebber R; Costa DS; Norman R; Janda M; Smith DP; Grimison P; Gamper EM; King MT
    Med J Aust; 2019 Jun; 210(11):499-506. PubMed ID: 31155722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.